Keywords: Biomarkers, Alzheimer's Disease
Motivation: Nicotinamide riboside (NR) supplementation has increased in popularity for treating neurodegenerative diseases and is attributed to elevated NAD+ levels. Effective monitoring of NR-mediated changes may highlight metabolic underpinnings of NR in dementia.
Goal(s): This study uses glutamate-CEST MRI to monitor changes in glutamate levels following NR supplementation in wild-type and 5XFAD mouse models of AD.
Approach: Mice (WT and AD) were treated with NR or a vehicle (placebo) for 12 weeks followed by GluCEST MRI.
Results: There was a significant GluCEST increase in AD mice compared to WT. Following NR, GluCEST decreased in AD mice, primarily in the hippocampus.
Impact: NR supplementation may help alleviate excitotoxicity in AD, thereby preventing neuronal cell death/degeneration. GluCEST provides an effective method for assessing changes in glutamate levels, allowing for monitoring excitotoxicity in patients presenting symptoms of AD and the effects of NR treatment.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords